HRZN Horizon Technology Finance Corp Insider Trading

Director Thomas J. Allison buys 6,000 shares of HRZN at $4.36; 5 other insiders also bought within 14 days as stock trades -48.5% from 52-week high.

Director Thomas J. Allison purchased 6,000 shares at $4.36, increasing his holdings by 11.9% to 56,617 shares. This transaction occurred alongside a coordinated cluster pattern—5 other insiders also bought within the past 14 days—suggesting broad-based insider accumulation. The stock currently trades at -48.5% from its 52-week high of $8.46, placing it near the lower end of its 52-week range, and has recovered 6.3% over the past 90 days. Notable context: the company reported net income of $2.8M and a P/E of 13.62, but was unprofitable over its most recent full fiscal year, presenting a mixed fundamental picture. The convergence of multiple insider purchases at depressed valuation levels warrants attention to whether this reflects informed positioning or a broader capital structure reassessment.

Director Kimberley Ann O'Connor buys 10,000 shares of HRZN at $4.37; cluster buy pattern with 5 other insiders in 14 days

Kimberley Ann O'Connor purchased 10,000 shares at $4.37, establishing an initial position while the stock trades at $4.34 (current price), down 48.7% from its 52-week high of $8.46. The transaction occurs within a cluster: 5 other insiders have also bought within the past 14 days. The company reported net income of $2,778,000.00, though it was unprofitable over its most recent full fiscal year. The P/E ratio stands at 13.56 against a market cap of $296,253,221.74. This coordinated insider buying activity coincides with a period where the stock remains substantially depressed relative to its recent range, though the near-term price trajectory shows modest recovery (+0.2% over 30 days, +0.5% over 90 days).

Director Jonathan Joseph Goodman buys 6,000 HRZN shares at $4.32; stock now $4.34 after 48.7% decline from 52-week high.

Jonathan Joseph Goodman, a director of Horizon Technology Finance Corp, purchased 6,000 shares at $4.32 on 2026-06-09, increasing his holdings from 2,312 to 8,312 shares (a 259.5% increase). The transaction price represents current conditions well below the 52-week high of $8.46 (down 48.7%). His cross-ticker track record shows 1 prior buy with an average 90-day return of -12.7%, and his same-ticker prior trade in HRZN on 2024-08-05 experienced a 90-day decline of 12.7%, indicating a pattern of poorly-timed purchases. The company is unprofitable on a full-year basis despite current net income of $2.8M, creating uncertainty about near-term earnings trajectory.

CFO Daniel R. Trolio buys 11,500 shares of HRZN at $4.34; holdings triple to 15,023 shares amid cluster buy pattern

Daniel R. Trolio, Executive VP and CFO, purchased 11,500 shares at $4.34 on 2026-06-10, increasing his holdings from 3,523 shares to 15,023 shares—a +326.4% increase in his position. The stock is trading at $4.34, which is -48.7% from its 52-week high of $8.46. Notably, 2 other insiders also bought within the past 14 days, establishing a cluster buy pattern. While the company reported net income of $2.8M with a P/E of 13.56, it was unprofitable over its most recent full fiscal year, creating a contrast between current profitability and recent full-year losses that warrants investor attention.

Chief Investment Officer Paul G Seitz purchased 11,477 shares of HRZN at $4.35 on 2026-06-09; holdings surge 1500.3%; 3 other insiders also bought in 14 days

Paul G Seitz, the Chief Investment Officer, purchased 11,477 shares at $4.35, expanding his holdings from 765 shares to 12,242 shares—a 1500.3% increase in his position. This large-scale accumulation by a senior executive is noteworthy; Seitz holds the CIO title, positioning him to evaluate investment merit and capital allocation decisions. The transaction occurs as part of a cluster pattern with 3 other insiders buying within the past 14 days, suggesting broad internal confidence in the security at the $4.35 price point. However, context is mixed: the company reported a negative net income over its most recent full fiscal year despite current reported net income of $2.8M, the stock trades at -48.7% from its 52-week high of $8.46, and the current price of $4.34 sits near the transaction price, indicating no material post-purchase upside yet. The magnitude of this purchase by a CIO, combined with corroborating buys from other insiders, warrants attention to whether this signals renewed confidence in the company's turnaround trajectory.

CEO Michael Balkin buys 100,000 shares of HRZN at $4.34, +81.0% increase in holdings, stock -48.7% from 52-week high

Michael Balkin, Chief Executive Officer, purchased 100,000 shares at $4.34 on 2026-06-09, expanding his holdings from 123.5K to 223.5K shares. The stock trades 48.7% below its 52-week high of $8.46, and his prior buy at this ticker on 2024-12-16 delivered a 90d return of +7.8%, while a 2024-08-05 purchase yielded -10.8% over 90 days—a 50% hit rate on same-ticker buys. The company reported net income of $2.8M but was unprofitable over its most recent full fiscal year, creating a disconnect between recent profitability and underlying fundamentals that warrants scrutiny of the investment thesis.

Director Balkin Michael buys 20,000 shares of HRZN at $8.53; stock down -35.5% from 52-week high, unprofitable year.

Balkin Michael, a director, purchased 20,000 shares at $8.53 on 2024-12-16, establishing an initial position in HRZN. The stock has declined sharply from its 52-week high of $13.63 and is currently trading at $8.79, down -19.4% over 90 days. Notably, his prior buy at this ticker on 2024-08-05 returned -10.8% over 90 days, and his cross-ticker track record shows a 0% 90-day win rate despite prior near-term gains. The company reported negative full-year net income despite current-period positive earnings of $7.3M, creating mixed financial signals. The purchase occurs at a depressed valuation but within a persistent downtrend, with no clear evidence that the timing will reverse the recent pattern observed in this insider's prior activity at this ticker.

President Michaud purchases 8,000 HRZN shares at $9.31; stock at -31.5% from 52-week high of $13.63.

Gerald A. Michaud, President, purchased 8,000 shares at $9.31, increasing his holdings from 161,309 to 169,309 shares (+5.0% net change). The stock is currently trading at $9.34, down 31.5% from its 52-week high of $13.63 and down 15.7% over the past 90 days. Michaud's single prior open-market purchase at HRZN in March 2024 returned +1.7% over 90 days, indicating a pattern of well-timed entry points. However, context matters: the company reported negative full-year net income despite a current P/E of 4.72, and the stock remains in a downtrend. The purchase occurs after substantial price decline, but absent forward guidance or catalysts in the filing, the transaction alone does not clearly signal conviction about a turnaround.

Director Joseph Savage buys 9,500 shares (9.5K) at $9.28 blended avg for $88,150; builds stake to 59.5K shares

Joseph Savage, a director at Horizon Technology Finance Corp, made 2 separate purchases totaling 9,500 shares for $88,150.00 on 2024-11-13 and 2024-11-14, at prices of $9.35 and $9.20 respectively (blended $9.28). His holdings increased 19.0% from 50,000 shares to 59,500 shares. The stock is currently at $9.20, near the bottom of its 52-week range of $9.20–$13.63, down 32.5% from the 52-week high and -12.7% over the past 30 days. The company reported net income of $7,278,000.00 with a P/E of 4.65, but was unprofitable over its most recent full fiscal year. The director's transaction occurs against a backdrop of recent stock weakness and depressed valuation metrics, though the purchase was executed across two trading days rather than as a single discrete event.

Director Goodman buys 2,313 HRZN shares at $10.81; stock down 20.3% from 52-week high.

Jonathan Joseph Goodman, a Director, purchased 2,313 shares at $10.81 on 2024-08-05, establishing a position for the first time. The purchase occurs as Horizon Technology Finance trades at $10.86 current price, down 20.3% from its 52-week high of $13.63, and the company carries negative net income of $-9,133,000.00 for its most recent full fiscal year. The transaction's modest scale relative to market cap and the unprofitable operational context limit the inference of strong conviction, though a director's initial stake purchase warrants investor attention given the company's challenged financial performance.